SPDR S&P Pharmaceuticals ETF
XPH
XPH
72 hedge funds and large institutions have $138M invested in SPDR S&P Pharmaceuticals ETF in 2023 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 16 increasing their positions, 18 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
more ownership
Funds ownership: →
11% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 18
36% less call options, than puts
Call options by funds: $649K | Put options by funds: $1.01M
Holders
72
Holding in Top 10
–
Calls
$649K
Puts
$1.01M
Top Buyers
| 1 | +$19.3M | |
| 2 | +$16.5M | |
| 3 | +$3.14M | |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
+$2.15M |
| 5 |
TCA
Taconic Capital Advisors
New York
|
+$1.66M |
Top Sellers
| 1 | -$3.21M | |
| 2 | -$2.92M | |
| 3 | -$1.18M | |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$1.11M |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$955K |